Neurology ·
Language model platform talks with epilepsy patients during EEG monitoring; AI-assisted EEG review cuts reading time; thalamic DBS harms tracked
Listen to this post
read by AI voices · all episodesTHE SHORT READ
University of Pennsylvania researchers described in Nature Medicine a large language model platform that links EEG monitoring to a smartphone app and converses with people with epilepsy. Other studies tested expert review of AI-flagged long-term EEG and tracked harmful ideation or behavior after thalamic deep brain stimulation for epilepsy, and a pivotal trial implanted its first U.S. patient with an ultra-thin migraine neuromodulation device.
THE DETAILS
- AI Oct 13, 2026University of Pennsylvania researchers reported in Nature Medicine an inpatient prototype that links scalp and intracranial electroencephalography (EEG) to a secure, large language model-based AI that communicates with patients through a smartphone app. The AI processes biomarkers of sleep, medication, cognition and seizure probability and uses patient feedback to retrain its seizure detector. It was validated in 13 patients undergoing video-EEG monitoring, 11 with scalp and two with intracranial recordings. In a pseudoprospective simulation, seizure detectors improved precision from patient feedback alone, without expert intervention, the authors said.Sources: Nature Medicine, PubMed
- AI Oct 17, 2026Researchers reported in Epilepsia a test of autoSCORE, a clinically approved implementation of the SCORE-AI model integrated into an EEG reader, on 78 adult long-term monitoring recordings, with epilepsy monitoring unit discharge diagnosis as the reference. Experts reviewing the AI's detections took a median 2.2 minutes versus 52.4 minutes for conventional review, a 95.8% median reduction, with higher sensitivity (.88 versus .69). The hybrid approach's higher accuracy versus conventional reading (.75 versus .68) was not significant after correction, and fully automated analysis was less accurate (.55). Authors included researchers from Natus Medical.
- Technology Oct 15, 2026Salvia BioElectronics said Oct. 15 that the first U.S. patient was implanted with the MySalvia System at Vista Clinical Research in Newnan, Georgia, in RECLAIM-II, a pivotal, multicenter, randomized, double-blind, controlled trial for the preventive treatment of adults with resistant migraine. The system targets nerves involved in migraine through two ultra-thin implants, and patients use a small wearable device to activate the therapy twice daily, according to the company. The trial, which follows Food and Drug Administration investigational device exemption approval, is expected to enroll about 150 patients at more than 20 U.S. sites.Source: Salvia BioElectronics
- Research Oct 12, 2026An Emory University review in Epilepsia of 90 patients treated with deep brain stimulation of the anterior nucleus of the thalamus for drug-resistant epilepsy found that 11 (12.2%) developed new or worsening self- or other-directed harmful ideation or behavior. Preoperative harmful ideation or behavior predicted it (odds ratio 8.07, P = .003), while the volume and connectivity of stimulated tissue did not differ. Symptoms resolved in eight patients after a change from high- to low-frequency stimulation and in three after contact and amplitude changes.
The weekly innovation roundup for neurology, published every Sunday for the week before; every item links to its sources. Latest neurology news · All specialties